So I have read the Roth report. Unfortunately I cannot share it due to compliance restrictions on distribution. What I can tell you though is that this is a proper investment house and a quality analyst. This is not paid for research. Instead there is a disclaimer which states that Roth expects to do capital markets business within 3 months. Roth has a history of raising capital for SMID cap companies. The fact that Roth has picked up coverage is a clear positive. As for details in the report there is nothing that has not already been discussed on this forum. The main point is the $10 price target is based ONLY on $1bn peak sales from the narrowly defined patient group in BETonMACE - i.e only for CV indication for Type 2 diabetics post ACS.